Video

Expert Discusses Mutations in Melanoma

Author(s):

Alan Shain, PhD
Conference|SMR Congress

Alan Shain, PhD, postdoctoral scholar, UCSF School of Medicine, discusses the role of genetics in melanoma.

Alan Shain, PhD, postdoctoral scholar, University of California, San Francisco School of Medicine, discusses the role of genetics in melanoma.

There has been excitement in the field of genomics for patients with melanoma for some time now, states Shain.

A problem with sequencing melanoma at a late stage is that there is no way to know the order in which the mutations occurred. But, by understanding the order of mutations, biomarkers for progression may be revealed, Shain says.

<<< View more from the World Congress of Melanoma

Related Videos
Jacob Sands, MD, oncology medical director, International Patient Center, Dana-Farber Cancer Institute; assistant professor, Harvard Medical School
Fred R. Hirsch, MD, PhD, executive director, Center for Thoracic Oncology, The Tisch Cancer Institute at Mount Sinai; Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Related Content
Jonathan W. Riess, MD, MS
July 26th 2024

Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Lajos Pusztai, MD, DPhil
July 25th 2024

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS
March 6th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

Sarah Sammons, MD
July 22nd 2024

Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium

Pedram Razavi, MD, PhD
July 22nd 2024

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management